At present, only injectable drugs are available for treating multiple sclerosis. So clinical trials indicating that the drug fingolimod might be a step towards an oral treatment for the disease are exciting indeed.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Kappos, L. et al. N. Engl. J. Med. 362, 387–401 (2010).
Cohen, J. A. et al. N. Engl. J. Med. 362, 402–415 (2010).
Sospedra, M. & Martin, R. Annu. Rev. Immunol. 23, 683–747 (2005).
The IFNB Multiple Sclerosis Study Group Neurology 43, 655–661 (1993).
Johnson, K. P. et al. Neurology 45, 1268–1276 (1995).
Miller, D. H. et al. N. Engl. J. Med. 348, 15–23 (2003).
Pascual, A. M. et al. Mult. Scler. 15, 1303–1310 (2009).
Bielekova, B. et al. Nature Med. 6, 1167–1175 (2000).| Article |
Yednock, T. A. et al. Nature 356, 63–66 (1992).
Chiba, K. et al. J. Immunol. 160, 5037–5044 (1998).
Mandala, S. et al. Science 296, 346–349 (2002).
Brinkmann, V. et al. J. Biol. Chem. 277, 21453–21457 (2002).
Cinamon, G. et al. Nature Immunol. 5, 713–720 (2004).
Miron, V. E. et al. Ann. Neurol. 63, 61–71 (2008).
Pinschewer, D. D. et al. J. Immunol. 164, 5761–5770 (2000).
Premenko-Lanier, M. et al. Nature 454, 894–898 (2008).
Leypoldt, F. et al. Neurology 72, 1022–1024 (2009)
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author has received support for educational events/institute symposia from Teva/Sanofi & Aventis, Biogen, Merck & Serono, Novartis, Bayer & Schering. The author has received compensation for advisory functions from Biogen, Teva/Sanofi, Merck & Serono, and Bayer & Schering.
Rights and permissions
About this article
Cite this article
Martin, R. Closing in on an oral treatment. Nature 464, 360–361 (2010). https://doi.org/10.1038/464360a
Published:
Issue Date:
DOI: https://doi.org/10.1038/464360a
This article is cited by
-
Extracellular and intracellular sphingosine-1-phosphate in cancer
Cancer and Metastasis Reviews (2011)
-
Sphingosine-1-phosphate: a potential therapeutic target for rheumatoid arthritis
Molecular Biology Reports (2011)